Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

en target lesion revascularization (TLR, repeat procedures driven by lack of blood supply).

-- A 32 percent reduction in the risk of TVF compared to TAXUS (10.7 percent for XIENCE V vs. 15.4 percent for TAXUS, p-value=0.04)*.

-- Low rates of stent thrombosis between one and two years, defined as very late stent thrombosis, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.3 percent for XIENCE V and 1.0 percent for TAXUS) and per the SPIRIT III protocol (0.2 percent for XIENCE V and 1.0 percent for TAXUS). The ARC definition of late stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials.

"Today's approval of XIENCE V is a reflection of Abbott's ongoing commitment to bring innovation-driven, leading-edge medical technologies to the people who need them," added Capek. "With one of the largest, most seasoned vascular sales forces in the United States and with the ability to supply more than half the worldwide market, we will begin shipping units of XIENCE V immediately to meet physician demand for this much awaited, next- generation technology."

More About XIENCE V

XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

The XIENCE V drug coated stent will be available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review for approval by Japan's Ministry of Health, Lab
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... ... applications such as animal waste reduction, bioremediation, wastewater treatment, aquaculture and grease, ... announced today that it will be showcasing, ManureMagic™, its industry-leading product for ...
(Date:7/3/2015)... , July 3, 2015 /PRNewswire/ ... hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Innovation in Science" -jatkokoulutusohjelmaan 22.7.2015 ... Gesellschaftin (LBG) tekemän, kansainvälisiä tutkijoita ... terveystieteiden kaksi suurinta haastetta ovat ...
(Date:7/3/2015)... ... July 03, 2015 , ... The ... companies and professional service industries alike-- typically known for its consummate professionalism-- embarks ... a good cause and break from their day jobs. , "Our motto has ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis ... from 2015 to 2020. The bioscience market is expected to grow at the highest ... of failure analysis equipment in the research labs and academic institutions for root cause ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3The Alexander Group Declares Their Independence with a Bit of Levity 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... Feb. 28, 2012  Thomson Reuters announced the availability ... that speeds access to critical life sciences research ... sciences platform, Thomson Reuters Cortellis. ... sophisticated application programming interfaces (APIs) to enhance the ...
... KENNESAW, Ga., Feb. 28, 2012 MiMedx Group, Inc. ... patent protected regenerative biomaterials and bioimplants processed from human ... ended December 31, 2011. Full Year ... ended December 31, 2011, with revenue of $7.8 million, ...
... Ultragenyx Pharmaceutical Inc., a biotechnology company focused on ... today announced that the FDA Office of Orphan ... UX003 for the treatment of MPS 7.  MPS ... storage disorder characterized by a deficiency of the ...
Cached Biology Technology:Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services 2MiMedx Group Announces 2011 Results 2MiMedx Group Announces 2011 Results 3MiMedx Group Announces 2011 Results 4MiMedx Group Announces 2011 Results 5MiMedx Group Announces 2011 Results 6MiMedx Group Announces 2011 Results 7MiMedx Group Announces 2011 Results 8Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3
(Date:7/2/2015)... June 25, 2015 ... addition of the "Natural Language Processing Market ... IVR, OCR, Pattern & Image Recognition) - Worldwide ... The key vendors occupying the market ... Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute Inc., ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... that places one at risk for Alzheimer,s disease does not ... by Florida State University. FSU Psychology Professor Natalie Sachs-Ericsson ... APOE epsilon 4 allele is a risk factor for African-Americans ... mainstream belief that the gene is only a risk factor ...
... is one month before ESOF 2008 gets underway. Some major announcements ... Registration: If you have NOT registered please note: Online ... Online Media Centre at www.esof2008.org ESOF 2008 ... officially launched in Barcelona on Monday July 7, 11am and ...
... future needs just as we humans can by ... Osvath,s research, from Lunds University Cognitive Science in Sweden, ... planning capacities in non-human species. Their findings are published ... . The complex skill of future planning is ...
Cached Biology News:Known genetic risk for Alzheimer's in whites also places blacks at risk 2Great apes think ahead 2
... standard water based mounting medium for immunohistology. ... preservation of peroxidase and alkaline phosphatase stained ... and exhibits excellent optical characteristics. Crystal / ... that permits the long-term storage of antigens ...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
Biology Products: